"Disrupting the tumour micro environment"
About Us
We are a clinical stage biotechnology company
working on a new and better way to treat cancer.
We focus on extending patient survival
with a strong emphasis on the quality of life.
Addressing tumour growth by stimulating a targeted immune response to disrupt the tumour micro environment.
We have an approved Phase I/II clinical trial in a
combination treatment for mutated colorectal cancer and a
pipeline plan in multiple indications of solid tumours
Unique Novel Approach
How are we different ?
Target the tumour micro environment and not the tumour
Active stimulation of antibody response to target growth factors active in cancer cell proliferation
Lower toxicity offering a better quality of life during treatment
Huge Potential
We aim to produce medicines that are the preferred choice for use as a mono therapy and as combinations with existing cancer treatments
We augment existing treatments without adding toxicity
We can target many different indications of solid tumour cancers
A lower toxic profile makes us the preferred choice for mono or combination treatment